Opioid Abuse

Categories: Mental diseases

Aliases & Classifications for Opioid Abuse

MalaCards integrated aliases for Opioid Abuse:

Name: Opioid Abuse 12 54 15 71
Opioid-Related Disorders 43


External Ids:

Disease Ontology 12 DOID:11206
ICD9CM 34 305.5
MeSH 43 D009293
SNOMED-CT 67 5602001
ICD10 32 F11.1
UMLS 71 C0029095

Summaries for Opioid Abuse

Disease Ontology : 12 A substance abuse that involves the recurring use of opioid drugs despite negative consequences.

MalaCards based summary : Opioid Abuse, also known as opioid-related disorders, is related to opioid addiction and personality disorder. An important gene associated with Opioid Abuse is OPRM1 (Opioid Receptor Mu 1), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Valproic acid and Peginterferon alfa-2b have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and bone, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Opioid Abuse

Diseases related to Opioid Abuse via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 128)
# Related Disease Score Top Affiliating Genes
1 opioid addiction 30.2 PNOC OPRM1 OPRK1 OPRD1 DRD2 CCK
2 personality disorder 30.0 DRD3 DRD2 CCK
3 polysubstance abuse 30.0 DRD3 DRD2
4 alcohol use disorder 29.8 OPRM1 DRD3 DRD2 DRD1
5 heroin dependence 29.6 PDYN OPRM1 OPRD1 DRD2 DRD1
6 sexual disorder 29.5 DRD3 DRD2 CYP2D6
7 neonatal abstinence syndrome 29.3 PNOC PDYN OPRM1 OPRL1 OPRK1 OPRD1
8 mental depression 29.2 DRD3 DRD2 DRD1 CYP2D6
9 constipation 29.1 PDYN OPRM1 OPRL1 OPRK1 OPRD1 CYP2D6
10 cocaine dependence 29.1 PDYN OPRM1 OPRK1 OPRD1 DRD3 DRD2
11 opiate dependence 28.3 PENK PDYN OPRM1 OPRL1 OPRK1 OPRD1
12 anxiety 28.3 PNOC PDYN OPRM1 OPRL1 OPRK1 DRD3
13 substance abuse 28.3 PDYN OPRM1 OPRL1 OPRK1 OPRD1 DRD5
14 attention deficit-hyperactivity disorder 28.1 OPRM1 DRD5 DRD3 DRD2 DRD1 CYP2D6
15 drug dependence 28.0 PNOC PENK PDYN OPRM1 OPRL1 OPRK1
16 pain agnosia 27.8 PNOC PENK PDYN OPRM1 OPRL1 OPRK1
17 withdrawal disorder 27.8 PNOC PENK PDYN OPRM1 OPRL1 OPRK1
18 psychotic disorder 27.7 PDYN OPRM1 DRD5 DRD3 DRD2 DRD1
19 schizophrenia 27.6 PDYN OPRM1 DRD5 DRD3 DRD2 DRD1
20 alcohol dependence 27.2 PNOC PDYN OPRM1 OPRL1 OPRK1 OPRD1
21 chronic pain 10.6
22 schaaf-yang syndrome 10.3 OPRM1 OPRL1 OPRD1
23 paine syndrome 10.2 PNOC OPRM1 OPRL1
24 trigeminal nerve disease 10.2 OPRM1 OPRL1 OPRK1 OPRD1
25 trigeminal neuralgia 10.2 OPRM1 OPRL1 OPRK1 OPRD1
26 galactorrhea 10.2 DRD2 CYP2D6
27 early-onset schizophrenia 10.2 DRD2 DRD1
28 barbiturate abuse 10.2 OPRM1 CLMP
29 antisocial personality disorder 10.1
30 mood disorder 10.1
31 kleptomania 10.1 OPRK1 DRD3 DRD2
32 spinocerebellar ataxia 23 10.0 PDYN OPRM1 OPRL1 OPRK1 OPRD1
33 hepatitis a 10.0
34 hypogonadism 10.0
35 degenerative disc disease 10.0
36 47,xyy 10.0
37 fibromyalgia 9.9 PNOC OPRM1 OPRK1 OPRD1 DRD2
38 tardive dyskinesia 9.9 DRD3 DRD2 CYP2D6
39 eating disorder 9.9 OPRM1 DRD3 DRD2 CCK
40 diarrhea 9.8 OPRM1 OPRK1 OPRD1 CYP2D6 CCK
41 bipolar i disorder 9.8 DRD3 DRD2 DRD1
42 dowling-degos disease 1 9.8
43 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 9.8
44 ocular motor apraxia 9.8
45 periodontitis, chronic 9.8
46 encephalopathy, progressive, early-onset, with episodic rhabdomyolysis 9.8
47 peripheral vascular disease 9.8
48 deficiency anemia 9.8
49 cardiac arrest 9.8
50 pertussis 9.8

Graphical network of the top 20 diseases related to Opioid Abuse:

Diseases related to Opioid Abuse

Symptoms & Phenotypes for Opioid Abuse

GenomeRNAi Phenotypes related to Opioid Abuse according to GeneCards Suite gene sharing:

# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-2 9.53 MAPK10
2 Decreased viability GR00221-A-3 9.53 MAPK10
3 Decreased viability GR00249-S 9.53 COMMD3 MAPK10 NPFF OPRK1 OPRL1
4 Decreased viability GR00381-A-1 9.53 CYP2D6
5 Decreased viability GR00386-A-1 9.53 CCK CLMP DRD1 ITIH4 OPRL1
6 Decreased viability GR00402-S-2 9.53 CYP2D6 OPRK1 OPRM1

MGI Mouse Phenotypes related to Opioid Abuse:

# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.27 CCR5 CLMP DRD1 DRD2 DRD3 DRD5
2 homeostasis/metabolism MP:0005376 10.1 CCK CCR5 CLMP DRD1 DRD2 DRD3
3 digestive/alimentary MP:0005381 9.92 CCR5 CLMP DRD1 DRD2 DRD3 OPRK1
4 integument MP:0010771 9.81 DRD1 DRD2 OPRD1 OPRK1 OPRL1 OPRM1
5 nervous system MP:0003631 9.77 CCK CCR5 DRD1 DRD2 DRD3 DRD5
6 no phenotypic analysis MP:0003012 9.17 CCK DRD2 MAPK10 OPRD1 OPRM1 PDYN

Drugs & Therapeutics for Opioid Abuse

Drugs for Opioid Abuse (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 268)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
Peginterferon alfa-2b Approved Phase 4 99210-65-8, 215647-85-1
Ribavirin Approved Phase 4 36791-04-5 37542
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
Morphine Approved, Investigational Phase 4 57-27-2 5288826
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
Sodium citrate Approved, Investigational Phase 4 68-04-2
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
Menthol Approved Phase 4 2216-51-5 16666
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
Rifapentine Approved, Investigational Phase 4 61379-65-5 6323497
Isoniazid Approved, Investigational Phase 4 54-85-3 3767
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
Cobicistat Approved Phase 4 1004316-88-4
Velpatasvir Approved, Investigational Phase 4 1377049-84-7 67683363
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
Nicotine Approved Phase 4 54-11-5 942 89594
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
Methadone Approved Phase 4 76-99-3 4095
Oxymorphone Approved, Investigational, Vet_approved Phase 4 76-41-5 5284604
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
Trichostatin A Experimental Phase 4 58880-19-6
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
26 Adrenergic alpha-Agonists Phase 4
27 Adrenergic Agents Phase 4
28 Adrenergic Agonists Phase 4
29 Anticonvulsants Phase 4
30 Antipyretics Phase 4
31 Anti-Anxiety Agents Phase 4
32 Hypnotics and Sedatives Phase 4
33 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4
34 Desvenlafaxine Succinate Phase 4 386750-22-7
35 Immunologic Factors Phase 4
36 Interferon-alpha Phase 4
37 Interferon alpha-2 Phase 4
38 Ketorolac Tromethamine Phase 4
39 Respiratory System Agents Phase 4
40 Antitussive Agents Phase 4
41 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
42 Anti-Infective Agents Phase 4
43 Antitubercular Agents Phase 4
44 Anti-Bacterial Agents Phase 4
45 Antibiotics, Antitubercular Phase 4
46 Antimetabolites Phase 4
47 Sodium Channel Blockers Phase 4
48 Diuretics, Potassium Sparing Phase 4
49 Excitatory Amino Acid Antagonists Phase 4
50 Anesthetics, General Phase 4

Interventional clinical trials:

(show top 50) (show all 641)
# Name Status NCT ID Phase Drugs
1 An Evaluation of Innovative Methods for Integrating Buprenorphine Opioid Treatment in HIV Primary Care Settings Unknown status NCT00124358 Phase 4 Buprenorphine
2 SPNS Buprenorphine and Integrated HIV Care Evaluation and Support Center: Integration of Buprenorphine and HIV Treatment Using the OASIS Model Unknown status NCT00241930 Phase 4
3 Effects of Ketamine On Precipitated Opioid Withdrawal Under General Anaesthesia Completed NCT00300794 Phase 4 Ketamine
4 An Open Multi-center Trial of Suboxone® (Buprenorphine/Naloxone) Treatment Among Opiate-Dependent Subjects Completed NCT00901875 Phase 4 Buprenorphine + naloxone (Suboxone);Buprenorphine + naloxone (Suboxone)
5 Feasibility Study of Take-Home LAAM Medication Completed NCT00000300 Phase 4 LAAM
6 Intervention of HIV, Drug Use and the Criminal Justice System in Malaysia Completed NCT02396979 Phase 4 Methadone
7 Buprenorphine/Nx Treatment of Heroin Dependence-A Compassionate Use Study Completed NCT00015340 Phase 4 Buprenorphine/naloxone
8 A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects Completed NCT00605033 Phase 4 Suboxone, Buprenorphine Hydrochloride + Naloxone, SCH 484;Subutex, Buprenorphine Hydrochloride, SCH 28444
9 A Single Center, Randomized, 2 Way Cross-Over, Phase 4 Study Comparing Usability of Zubsolv Sublingual Tablets 5.7/1.4 to Suboxone Sublingual Film 8/2 Including Ease of Use, Taste Preference, Dissolution Time, Desire to Abuse, and Overall Acceptance In Buprenorphine/Naloxone Treated Opioid Dependent Population Completed NCT02038790 Phase 4 Suboxone Sublingual Film;Zubsolv sublingual tablets
10 Neurocognitive Effects of Opiate Agonist Treatment Completed NCT01733693 Phase 4 Buprenorphine;Methadone
11 Feasibility, Mechanism of Action and Potential Side Effects of Extended Release Depot Naltrexone in Opioid Dependent Patients Completed NCT01471145 Phase 4 Naltrexone
12 A Randomized Controlled Trial Comparing Buprenorphine and Methadone for Opioid Dependent Chronic Pain Patients Completed NCT00879996 Phase 4 Methadone;Buprenorphine/naloxone
13 A Phase 4, Pilot, Open-label Study of VIVITROL in the Prevention of Re-arrest and Re-incarceration Completed NCT01453374 Phase 4 VIVITROL 380mg
14 Administration of Acetazolamide to Prevent Remifentanil Induced Hyperalgesia: Randomize Double Blind Clinical Trial Completed NCT02992938 Phase 4 Acetazolamide;Placebo Oral Tablet
15 Integrating Buprenorphine Into the SFGH AIDS Program (Patient Evaluation Study) Completed NCT00263458 Phase 4
16 Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM) Completed NCT00798538 Phase 4
17 A Multi-center, Open-Label, 24-Week, Follow-Up Study to Assess Safety, Efficacy, and Treatment Adherence For Maintenance Treatment of Opioid Dependence With OX219 Completed NCT01903005 Phase 4 Higher bioavailability BNX sublingual tablets
18 Relapse Prevention to Reduce HIV Among Women Prisoners Completed NCT00763958 Phase 4 Placebo;Buprenorphine
19 Treatment of Polydrug-Using Opiate Dependents During Withdrawal Completed NCT00367874 Phase 4 Buprenorphine;Valproate
20 Evaluation of Preference for a Buprenorphine-based Maintenance Therapy, After a Switch From Buprenorphine Alone (Subutex®) to the Buprenorphine/Naloxone Combination (Suboxone®), in Opioid-dependent Patients With Buprenorphine Maintenance Therapy Completed NCT00684073 Phase 4 buprenorphine;buprenorphine/naloxone
21 An Open-Label Pilot Study of Desvenlafaxine for Opioid-Dependent Patients With Comorbid Depression Completed NCT02200406 Phase 4 Desvenlafaxine
22 Attention Training for Opioid-maintained Cocaine Users Completed NCT01870882 Phase 4
23 A Comparison of PR Oxycodone/Naloxone and PR Oxycodone After Cardiac Surgery Completed NCT01374763 Phase 4 Oxycodone;Prolonged-release oxycodone/naloxone
24 Hepatitis C in a Cohort of Patients With Maintenance Therapy for Opiate Dependence - Prevalence, Severity and Outcome of Antiviral Therapy Completed NCT01045278 Phase 4 Pegylated interferon-alfa-2b and ribavirin
25 Buprenorphine Maintenance vs. Detoxification in Prescription Opioid Dependence Completed NCT00555425 Phase 4
26 Counseling for Primary Care Office-based Buprenorphine Completed NCT00595764 Phase 4
27 A Feasibility Study for Testing the Effects of Extended-release Naltrexone (Vivitrol) on Recidivism and Other Participant Outcomes in Drug Court Settings Completed NCT02978417 Phase 4 Naltrexone for extended-release injectable suspension;Oral naltrexone
28 AVINZA Control of Chronic Pain, Effectiveness and Safety Study (ACCESS 2008) A Multi-Center Study to Evaluate the Effectiveness and Tolerability of AVINZA for Chronic Moderate-Severe Pain: A Focus on Risk Minimization Assessment, Intervention and Outcomes Completed NCT00640042 Phase 4 morphine sulfate extended release capsules
29 Influence of Dexmedetomidine and Lidocaine on Opioid Consumption, Cognitive Function and Incidence of Neuropathic Pain in Laparoscopic Intestine Resection Completed NCT02616523 Phase 4 Dexmedetomidine;Lidocaine;Fentanyl
30 A Multicenter Safety Trial of Buprenorphine/Naloxone for the Treatment of Opiate Dependence Completed NCT00007527 Phase 4 naloxone;buprenorphine
31 A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users Completed NCT00604188 Phase 4 Suboxone (SCH 000484);Subutex (SCH 028444)
32 Gabapentin Regimens and Their Effects on Opioid Consumption Completed NCT03334903 Phase 4 Gabapentin
33 Multimodal Pain Management for Cesarean Delivery: A Randomized Control Trial Completed NCT02922985 Phase 4 Intravenous acetominophen;Ketorolac, intramuscular;Bupivacaine, subcutaneous;Normal saline
34 The Analgesic Efficacy of Continuous Sub-fascial Bupivacaine Infusion and Lidocaine Patches in Post-cesarean Patients With Opiate Use Disorder: A Comparative Efficacy Analysis Recruiting NCT04033562 Phase 4 Lidocaine patch
35 Buprenorphine Extended-release in Jail and at Re-entry: Open-label Randomized Controlled Trial vs. Daily Sublingual Buprenorphine-naloxone Recruiting NCT03604159 Phase 4 Buprenorphine Extended Release;Sublingual Buprenorphine (SUBOXONE, Zubsolv, or generic tablets)
36 Houston Emergency Opioid Engagement System (HEROES) Recruiting NCT03396276 Phase 4 Suboxone
37 Efficacy of Non-Opioid Analgesics in the Management of Pain Following Endoscopic Sinus Surgery: A Multi-Institutional Randomized Controlled Trial Recruiting NCT03783702 Phase 4 OxyCODONE 5 Mg Oral Tablet;Ibuprofen 600 Mg Oral Tablet;Acetaminophen 650 MG Oral Tablet
38 A Combination Study With Sub-Dissociative Ketamine and Fentanyl to Treat Moderate to Severe Pain in the Emergency Department Recruiting NCT03959852 Phase 4 Fentanyl;Ketamine
39 Randomized, Double Blinded, Trial Comparing Intrathecal Morphine With Placebo in Patients Undergoing Robotic Totally Endoscopic Beating Heart Coronary Revascularization and Intraoperative Extubation Recruiting NCT03241485 Phase 4 Intrathecal morphine;Placebo
40 Increasing Access to Hepatitis C Treatment in Opioid Endemic Rural Areas: The Kentucky Viral Hepatitis Treatment (KeY Treat) Study Recruiting NCT03949764 Phase 4 Sofosbuvir/velpatasvir (Epclusa®)
41 Long Acting Naltrexone for Opioid Addiction: the Importance of Mental, Physical and Societal Factors for Sustained Abstinence and Recovery Recruiting NCT03647774 Phase 4 Extended release naltrexone
42 A Randomized Clinical Trial of Single Dose Liposomal Bupivacaine Delivered Via VATS Intercostal Nerve Block vs. Continuous Bupivacaine Infusion Delivered Via Indwelling Subscapular Catheter After Surgical Stabilization of Rib Fractures Recruiting NCT03305666 Phase 4 Liposomal bupivacaine injection;Bupivacaine indwelling catheter
43 Addiction, HIV and Tuberculosis in Malaysian Criminal Justice Settings Recruiting NCT03089983 Phase 4 Naltrexone;Methadone;Isoniazid;Rifapentine
44 Evaluation of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Switch Followed by Sofosbuvir/Velpatasvir (SOF/VEL) Antiviral HCV Therapy Followed by Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) Simplification in HIV-HCV Co-Infected Subjects on Opioid Substitution Therapy - A Pilot Feasibility Study Recruiting NCT03549312 Phase 4 Genvoya;Epclusa;Biktarvy
45 Biomarkers of Disease and Response to Treatment in Opioid Addiction Active, not recruiting NCT02324725 Phase 4 Naltrexone
46 Bridging Care to HCV Treatment Among Opiate Dependent Patients on Buprenorphine/Naloxone Maintenance Therapy: A Pilot Study of Treating HCV With Epclusa at a Psychiatrist-staffed Outpatient Addiction Clinic Active, not recruiting NCT03235154 Phase 4 sofosbuvir/velpatasvir
47 Extended-Release Naltrexone Opioid Treatment at Jail Re-Entry Active, not recruiting NCT01999946 Phase 4 Extended-Release Naltrexone
48 Overlapping Buprenorphine Initiation and Full Agonist Opioid Discontinuation Among Patients on High-dose Long-term Full Agonist Opioid Therapy Who Have Opioid Physical Dependence Not yet recruiting NCT04228250 Phase 4 Stepwise increase in buprenorphine while continuing full agonist opioid until buprenorphine reaches therapeutic dose
49 A Prospective, Randomized Trial of the Effect of Standard of Care Reduced Dose Versus Full Dose Buprenorphine/Naloxone in the Perioperative Period on Pain Control and Post Operative Opioid Use Disorder Symptoms Not yet recruiting NCT03266445 Phase 4 buprenorphine/naloxone
50 Can Simplified and More Detailed Instructions Affect Post-Operative Narcotic Consumption Not yet recruiting NCT03534102 Phase 4 Improved Opioid-Tapering Instructions

Search NIH Clinical Center for Opioid Abuse

Cochrane evidence based reviews: opioid-related disorders

Genetic Tests for Opioid Abuse

Anatomical Context for Opioid Abuse

MalaCards organs/tissues related to Opioid Abuse:

Brain, Testes, Bone, Heart, Liver, Prostate, Spinal Cord

Publications for Opioid Abuse

Articles related to Opioid Abuse:

(show top 50) (show all 1241)
# Title Authors PMID Year
International Narcotics Research--31st Conference. 61 54
16049839 2000
Stigmatization of opioid addiction based on prescription, sex and age. 61
32447236 2020
Eye-Related Emergency Department Visits and The Opioid Epidemic: a 10-Year Analysis. 61
32223491 2020
Effects of preoperative opioid education on postoperative opioid use and pain management in orthopaedics: A systematic review. 61
32025140 2020
Dopamine D3 receptor-based medication development for the treatment of opioid use disorder: Rationale, progress, and challenges. 61
32376243 2020
Addiction associated N40D mu-opioid receptor variant modulates synaptic function in human neurons. 61
31481756 2020
Interactions between opioids and cannabinoids: Economic demand for opioid/cannabinoid mixtures. 61
32497977 2020
Can Predictive Modeling Tools Identify Patients at High Risk of Prolonged Opioid Use After ACL Reconstruction? 61
32282466 2020
Who is HOT and who is LOT? Detailed characterization of prescription opioid-induced changes in behavior between 129P3/J and 129S1/SvlmJ mouse substrains. 61
31489753 2020
Identification of barriers to safe opioid prescribing in primary care: a qualitative analysis of field notes collected through academic detailing. 61
32540873 2020
Ten-year trend of opioid and non-opioid analgesic use in the French adult population. 61
32496599 2020
Recurrent Necrotizing Soft Tissue Infections with Atypical Pathogens after Injection Drug Abuse: Another Manifestation of the Opioid Crisis. 61
31910356 2020
Frequency of Early Refills for Opioids in the United States. 61
32529224 2020
Strategies to Standardize Opioid Research and Improve Clinical Pain Management. 61
32503762 2020
Quality improvement in post-operative opioid and benzodiazepine regimen in adolescent patients after posterior spinal fusion. 61
31925760 2020
[Gluteal compartment syndrome after immobilization following opioid abuse]. 61
32140813 2020
The atypical chemokine receptor ACKR3/CXCR7 is a broad-spectrum scavenger for opioid peptides. 61
32561830 2020
The Opioid Epidemic: Challenge to Military Medicine and National Security. 61
32077961 2020
The opioid epidemic in pediatrics: a 2020 update. 61
32371640 2020
Utilization of a Novel Opioid-Sparing Protocol in Primary Total Hip Arthroplasty Results in Reduced Opiate Consumption and Improved Functional Status. 61
32139187 2020
Replacement of current opioid drugs focusing on MOR-related strategies. 61
32165137 2020
Economic burden and clinical impact of preoperative opioid dependence for patients undergoing lower extremity bypass surgery. 61
31495675 2020
Outcomes of Randomized Clinical Trials of Interventions to Enhance Social, Emotional, and Spiritual Components of Wisdom: A Systematic Review and Meta-analysis. 61
32401284 2020
Trends and risk factors of adolescent opioid abuse/misuse: understanding the opioid epidemic among adolescents. 61
32396138 2020
Comparison of opioid use and prescribing patterns in orthopedic surgery in Japan and the United States: A JOA-AOA Traveling Fellowship Investigation. 61
31155440 2020
Female and male rats readily consume and prefer oxycodone to water in a chronic, continuous access, two-bottle oral voluntary paradigm. 61
32001238 2020
Heroin delay discounting and impulsivity: Modulation by DRD1 genetic variation. 61
31192519 2020
Opioid-Related Emergency Department Encounters: Patient, Encounter, and Community Characteristics Associated With Repeated Encounters. 61
31983498 2020
Independent association of tobacco use with opioid use disorder in patients of European ancestry with chronic non-cancer pain. 61
32126454 2020
The Opioid-Overdose Crisis and Fentanyl: The Role of Online Information Seeking via Internet Search Engines. 61
32285691 2020
The Role of a Certified Registered Nurse Anesthetist Led Acute Pain Service in Preventing Persistent Postoperative Opioid Use. 61
32175935 2020
Therapeutic potentials of NOP and MOP receptor coactivation for the treatment of pain and opioid abuse. 61
32255240 2020
Is Chronic Opioid Abuse Associated with Cerebral Atrophy? An Observational Study. 61
32565639 2020
Clinical profile and outcomes of opioid abuse gastroenteropathy: an underdiagnosed disease entity. 61
32088943 2020
A further assessment of a role for Toll-like receptor 4 in the reinforcing and reinstating effects of opioids. 61
30741729 2020
3D printed opioid medicines with alcohol-resistant and abuse-deterrent properties. 61
32087263 2020
Opioid-Prescribing Practices in Plastic Surgery: A Juxtaposition of Attendings and Trainees. 61
31907588 2020
Individual and county-level variation in outcomes following non-fatal opioid-involved overdose. 61
31919146 2020
Patient and institutional factors associated with postoperative opioid prescribing after common vascular procedures. 61
31519513 2020
Oral Opioid Use during Vaginal Delivery Hospitalizations. 61
30754053 2020
Prescription Drug Abuse Among Patients in Rural Dental Practices Reported by Members of the National Dental PBRN. 61
31385367 2020
Epidemiological and geospatial profile of the prescription opioid crisis in Ohio, United States. 61
32152360 2020
Opioid prescribing patterns of oral and maxillofacial surgery residents. 61
32035857 2020
Buprenorphine use for pain and suicidal ideation in severely suicidal patients. 61
32216493 2020
[A young woman's loperamide abuse for the achievement of euphoric effect]. 61
32285771 2020
Successful use of buprenorphine-naloxone medication-assisted program to treat concurrent pain and opioid addiction after cancer therapy. 61
32329886 2020
Clinical Characteristics and Outcomes of Patients With Heart Failure and Methamphetamine Abuse. 61
31618697 2020
Stringent Control of Opioids: Sound Public Health Measures, but a Step Too Far in Palliative Care? 61
32170510 2020
A deadly trend in fentanyl fatalities (England, 1998-2017). 61
31663152 2020
Non-opioid pharmacologic treatment of chronic spinal cord injury-related pain. 61
32182196 2020

Variations for Opioid Abuse

Expression for Opioid Abuse

Search GEO for disease gene expression data for Opioid Abuse.

Pathways for Opioid Abuse

Pathways related to Opioid Abuse according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
12.55 MAPK10 DRD5 DRD3 DRD2 DRD1
Show member pathways
12.47 MAPK10 DRD5 DRD3 DRD2 DRD1
5 12.09 DRD5 DRD3 DRD2 DRD1
6 12 MAPK10 DRD5 DRD2 DRD1
Show member pathways
11.73 PDYN DRD2 DRD1
Show member pathways
11.66 DRD5 DRD3 DRD2 DRD1
Show member pathways
10.62 DRD5 DRD3 DRD2 DRD1

GO Terms for Opioid Abuse

Cellular components related to Opioid Abuse according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.24 PNOC PENK PDYN OPRM1 OPRL1 OPRK1
2 integral component of plasma membrane GO:0005887 10.06 OPRM1 OPRL1 OPRK1 OPRD1 DRD5 DRD3
3 cell GO:0005623 10.03 OPRL1 OPRK1 NPFF DRD5 DRD3 DRD2
4 synapse GO:0045202 10.01 PNOC OPRK1 DRD5 DRD3 DRD2 DRD1
5 neuron projection GO:0043005 9.92 OPRM1 OPRL1 OPRK1 OPRD1 MAPK10
6 neuronal cell body GO:0043025 9.91 PNOC PENK PDYN OPRK1 CCK
7 dendrite GO:0030425 9.81 PNOC PENK PDYN OPRM1 OPRK1 NPFF
8 GABA-ergic synapse GO:0098982 9.72 DRD3 DRD2 DRD1
9 ciliary membrane GO:0060170 9.67 DRD5 DRD2 DRD1
10 integral component of presynaptic membrane GO:0099056 9.65 OPRM1 OPRK1 OPRD1 DRD2 DRD1
11 non-motile cilium GO:0097730 9.63 DRD5 DRD2 DRD1
12 integral component of postsynaptic membrane GO:0099055 9.62 OPRM1 OPRK1 DRD2 DRD1
13 9+0 non-motile cilium GO:0097731 9.57 DRD5 DRD1
14 dopaminergic synapse GO:0098691 9.56 DRD3 DRD2
15 perikaryon GO:0043204 9.5 PENK OPRM1 OPRK1 NPFF MAPK10 DRD2
16 spine apparatus GO:0097444 9.48 OPRM1 OPRD1
17 axon terminus GO:0043679 9.17 PNOC PENK PDYN OPRK1 OPRD1 NPFF

Biological processes related to Opioid Abuse according to GeneCards Suite gene sharing:

(show top 50) (show all 70)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.31 PNOC PENK OPRM1 OPRL1 OPRK1 OPRD1
2 chemical synaptic transmission GO:0007268 10.08 PNOC PENK PDYN OPRK1 NPFF DRD5
3 cell-cell signaling GO:0007267 10.05 DRD5 DRD3 DRD2 DRD1 CCR5
4 response to drug GO:0042493 10.04 NPFF DRD3 DRD2 DRD1
5 response to ethanol GO:0045471 9.99 PENK OPRM1 OPRK1 DRD3 DRD2
6 adenylate cyclase-modulating G protein-coupled receptor signaling pathway GO:0007188 9.95 DRD5 DRD3 DRD2 DRD1
7 adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway GO:0007193 9.92 OPRM1 OPRL1 OPRK1 OPRD1
8 sensory perception of pain GO:0019233 9.92 PENK OPRM1 OPRL1 OPRK1
9 response to toxic substance GO:0009636 9.91 PENK DRD3 DRD2
10 visual learning GO:0008542 9.91 DRD3 DRD2 DRD1 CCK
11 locomotory behavior GO:0007626 9.91 PENK OPRM1 OPRK1 DRD3 DRD2 DRD1
12 positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway GO:0051482 9.9 OPRL1 DRD3 DRD2 DRD1
13 excitatory postsynaptic potential GO:0060079 9.88 OPRM1 NPFF DRD2
14 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.88 OPRM1 OPRD1 DRD1
15 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.88 OPRM1 OPRK1 OPRD1
16 response to amphetamine GO:0001975 9.88 DRD5 DRD3 DRD2 DRD1
17 negative regulation of blood pressure GO:0045776 9.87 OPRL1 DRD5 DRD3 DRD2
18 response to radiation GO:0009314 9.86 PENK OPRM1 OPRK1
19 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.86 DRD5 DRD3 DRD2 DRD1
20 associative learning GO:0008306 9.85 DRD5 DRD2 DRD1
21 dopamine receptor signaling pathway GO:0007212 9.85 DRD5 DRD3 DRD2 DRD1
22 response to cocaine GO:0042220 9.85 OPRM1 OPRK1 DRD5 DRD3 DRD2 DRD1
23 behavioral response to cocaine GO:0048148 9.84 OPRK1 DRD3 DRD2 DRD1
24 estrous cycle GO:0044849 9.83 OPRM1 OPRL1 OPRK1
25 synaptic transmission, dopaminergic GO:0001963 9.83 DRD5 DRD3 DRD2 DRD1
26 negative regulation of voltage-gated calcium channel activity GO:1901386 9.82 OPRL1 DRD3 DRD2
27 prepulse inhibition GO:0060134 9.81 DRD3 DRD2 DRD1
28 behavioral response to ethanol GO:0048149 9.81 OPRM1 DRD3 DRD2
29 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.81 DRD5 DRD3 DRD2 DRD1
30 dopamine metabolic process GO:0042417 9.8 DRD3 DRD2 DRD1
31 eating behavior GO:0042755 9.8 OPRM1 OPRL1 OPRK1 OPRD1 CCK
32 regulation of sensory perception of pain GO:0051930 9.8 OPRM1 OPRL1 OPRK1 OPRD1 NPFF CCK
33 G protein-coupled receptor signaling pathway GO:0007186 9.8 PNOC PENK PDYN OPRM1 OPRL1 OPRK1
34 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.78 OPRM1 DRD5 DRD3 DRD1
35 opioid receptor signaling pathway GO:0038003 9.76 OPRM1 OPRL1 OPRK1 OPRD1
36 neuropeptide signaling pathway GO:0007218 9.76 PNOC PENK PDYN OPRM1 OPRL1 OPRK1
37 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.75 DRD3 DRD2 DRD1
38 transmission of nerve impulse GO:0019226 9.74 DRD5 DRD1
39 negative regulation of cytosolic calcium ion concentration GO:0051481 9.74 DRD3 DRD2
40 startle response GO:0001964 9.74 PENK DRD2
41 long-term synaptic depression GO:0060292 9.74 DRD5 DRD1
42 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.74 DRD3 DRD2
43 behavior GO:0007610 9.73 OPRL1 OPRK1
44 positive regulation of renal sodium excretion GO:0035815 9.73 DRD3 DRD2
45 positive regulation of urine volume GO:0035810 9.73 OPRL1 DRD2
46 grooming behavior GO:0007625 9.73 DRD2 DRD1
47 G protein-coupled receptor internalization GO:0002031 9.73 DRD3 DRD2
48 response to morphine GO:0043278 9.73 PENK OPRM1 OPRK1 NPFF DRD3 DRD2
49 maternal behavior GO:0042711 9.72 OPRK1 DRD1
50 striatum development GO:0021756 9.72 DRD2 DRD1

Molecular functions related to Opioid Abuse according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 10.09 OPRM1 OPRL1 OPRK1 OPRD1 DRD5 DRD3
2 peptide binding GO:0042277 9.78 OPRM1 OPRL1 OPRK1 OPRD1
3 neuropeptide hormone activity GO:0005184 9.76 PNOC PENK NPFF CCK
4 drug binding GO:0008144 9.71 DRD3 DRD2 CYP2D6
5 neuropeptide binding GO:0042923 9.62 OPRM1 OPRL1 OPRK1 OPRD1
6 opioid receptor binding GO:0031628 9.58 PNOC PENK PDYN
7 adrenergic receptor activity GO:0004935 9.56 DRD5 DRD3 DRD2 DRD1
8 opioid peptide activity GO:0001515 9.54 PNOC PENK PDYN
9 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.52 DRD3 DRD2
10 receptor serine/threonine kinase binding GO:0033612 9.51 OPRK1 OPRD1
11 dopamine neurotransmitter receptor activity, coupled via Gs GO:0001588 9.49 DRD5 DRD1
12 dopamine binding GO:0035240 9.46 DRD5 DRD3 DRD2 DRD1
13 opioid receptor activity GO:0004985 9.26 OPRM1 OPRL1 OPRK1 OPRD1
14 dopamine neurotransmitter receptor activity GO:0004952 8.92 DRD5 DRD3 DRD2 DRD1

Sources for Opioid Abuse

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....